Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Analysts rate Seaport Therapeutics “Hold” on average: Of nine covering firms, five recommend buying, three recommend holding, and one recommends selling. The average 12-month price target is $38.40.
• SPTX traded at $23.62, with a market capitalization of approximately $1.26 billion and a 12-month trading range of $14.85 to $24.48.
• The company reported a quarterly loss of $1.78 per share, missing the consensus estimate of a $0.71 loss; analysts expect a full-year loss of approximately $4.60 per share. Director Robert J. Hombach separately bought 13,000 shares at $18.14 each.

Seaport Therapeutics, Inc. (NASDAQ:SPTX - Get Free Report) has been given a consensus recommendation of "Hold" by the nine ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $38.40.

SPTX has been the subject of several research reports. Stifel Nicolaus assumed coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They set a "buy" rating and a $30.00 price objective for the company. Wolfe Research assumed coverage on Seaport Therapeutics in a report on Tuesday, July 7th. They issued a "hold" rating on the stock. Zacks Research raised Seaport Therapeutics to a "hold" rating in a research note on Wednesday, May 27th. BNP Paribas Exane downgraded Seaport Therapeutics to a "market perform" rating in a research note on Tuesday, May 26th. Finally, UBS Group lowered shares of Seaport Therapeutics to a "sell" rating in a research report on Tuesday, June 9th.

Seaport Therapeutics Trading Up 2.3%

Seaport Therapeutics stock opened at $23.62 on Friday. The stock's 50-day moving average price is $19.71. Seaport Therapeutics has a 12-month low of $14.85 and a 12-month high of $24.48. The firm has a market capitalization of $1.26 billion and a PE ratio of -2.28.

Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($1.07). Research analysts anticipate that Seaport Therapeutics will post -4.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Seaport Therapeutics

In other Seaport Therapeutics news, Director Robert J. Hombach bought 13,000 shares of the company's stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the transaction, the director owned 13,000 shares in the company, valued at $235,820. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source